Identification	O
and	O
functional	O
analysis	O
of	O
acute	O
myeloid	O
leukemia	O
susceptibility	O
associated	O
single	O
nucleotide	O
polymorphisms	O
at	O
non	O
-	O
protein	O
coding	O
regions	O
of	O
RUNX1	O
.	O


Little	O
is	O
known	O
about	O
the	O
susceptibility	O
to	O
acute	O
myeloid	O
leukemia	O
.	O


We	O
aim	O
to	O
search	O
non	O
-	O
protein	O
coding	O
regions	O
of	O
key	O
hematopoiesis	O
transcription	O
factors	O
for	O
genetic	O
variations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
susceptibility	O
.	O


We	O
genotyped	O
SNPs	O
of	O
RUNX1	O
P1	O
promoter	O
,	O
P2	O
promoter	O
,	O
+	O
23	O
enhancer	O
,	O
intron	O
5	O
.	O
2	O
enhancer	O
,	O
PU	O
.	O
1	O
promoter	O
,	O
CEBPA	O
promoter	O
,	O
and	O
CEBPE	O
promoter	O
from	O
acute	O
myeloid	O
leukemia	O
patients	O
and	O
healthy	O
controls	O
.	O


Rs2249650	O
and	O
rs2268276	O
at	O
RUNX1	O
intron	O
5	O
.	O
2	O
enhancer	O
were	O
found	O
to	O
be	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
susceptibility	O
.	O


Artificial	O
reporters	O
containing	O
different	O
rs2249650	O
and	O
rs2268276	O
alleles	O
showed	O
differential	O
activities	O
in	O
the	O
K562	B-TISSUE
cell	I-TISSUE
line	E-TISSUE
,	O
a	O
human	B-TISSUE
immortalized	I-TISSUE
myeloid	I-TISSUE
leukemia	I-TISSUE
line	E-TISSUE
.	O


Rs2249650	O
contributes	O
to	O
reporter	O
activities	O
more	O
than	O
rs2268276	O
.	O


Gel	O
shift	O
assay	O
is	O
consistent	O
with	O
the	O
luciferase	O
assay	O
.	O


Supershift	O
assay	O
indicated	O
that	O
one	O
potential	O
binding	O
protein	O
was	O
PU	O
.	O
1	O
.	O


To	O
sum	O
up	O
,	O
rs2268276	O
and	O
especially	O
rs2249650	O
may	O
be	O
qualified	O
as	O
new	O
acute	O
myeloid	O
leukemia	O
susceptibility	O
-	O
associated	O
SNPs	O
.	O
